{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:55:46Z","timestamp":1788382546430,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,27]]},"DOI":"10.7759\/cureus.51151","type":"journal-article","created":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T10:33:03Z","timestamp":1703673183000},"source":"Crossref","is-referenced-by-count":19,"title":["Novel Therapies in Diabetes: A Comprehensive Narrative Review of GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Beyond"],"prefix":"10.7759","author":[{"given":"Olusegun A","family":"Olanrewaju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Sheeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendar","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Salame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazdar","family":"yousef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamam","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30381-8","article-title":"Management of diabetes and hyperglycaemia in the hospital","volume":"9","author":"Pasquel FJ","year":"2021","unstructured":"Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021, 9:174-88. 10.1016\/S2213-8587(20)30381-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2021.154838","article-title":"Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes","volume":"123","author":"Yun JS","year":"2021","unstructured":"Yun JS, Ko SH. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism. 2021, 123:154838. 10.1016\/j.metabol.2021.154838","journal-title":"Metabolism"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12830","article-title":"Precision medicine in diabetes prevention, classification and management","volume":"9","author":"Xie F","year":"2018","unstructured":"Xie F, Chan JC, Ma RC. Precision medicine in diabetes prevention, classification and management. J Diabetes Investig. 2018, 9:998-1015. 10.1111\/jdi.12830","journal-title":"J Diabetes Investig"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4334-z","article-title":"The role of structured education in the management of hypoglycaemia","volume":"61","author":"Iqbal A","year":"2018","unstructured":"Iqbal A, Heller SR. The role of structured education in the management of hypoglycaemia. Diabetologia. 2018, 61:751-60. 10.1007\/s00125-017-4334-z","journal-title":"Diabetologia"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.949535","article-title":"Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction","volume":"13","author":"Yang S","year":"2022","unstructured":"Yang S, Li Y, Liu C, Wu Y, Wan Z, Shen D. Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction. Front Endocrinol (Lausanne). 2022, 13:949535. 10.3389\/fendo.2022.949535","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","author":"Amiel SA","year":"2019","unstructured":"Amiel SA, Aschner P, Childs B, et al.. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019, 7:385-96. 10.1016\/s2213-8587(18)30315-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1107-y","article-title":"Epidemiology of diabetes mellitus and cardiovascular disease","volume":"21","author":"Glovaci D","year":"2019","unstructured":"Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019, 21:21. 10.1007\/s11886-019-1107-y","journal-title":"Curr Cardiol Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-017-0284-5","article-title":"Dietary patterns and cardiovascular disease risk in people with type 2 diabetes","volume":"6","author":"Archundia Herrera MC","year":"2017","unstructured":"Archundia Herrera MC, Subhan FB, Chan CB. Dietary patterns and cardiovascular disease risk in people with type 2 diabetes. Curr Obes Rep. 2017, 6:405-13. 10.1007\/s13679-017-0284-5","journal-title":"Curr Obes Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy C","year":"2021","unstructured":"Caussy C, Aubin A, Loomba R. The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr Diab Rep. 2021, 21:15. 10.1007\/s11892-021-01383-7","journal-title":"Curr Diab Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0860-y","article-title":"Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management","volume":"18","author":"Luo F","year":"2019","unstructured":"Luo F, Das A, Chen J, Wu P, Li X, Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol. 2019, 18:54. 10.1186\/s12933-019-0860-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi P","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al.. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019, 157:107843. 10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","unstructured":"2. Classification and diagnosis of diabetes. standards of medical care in diabetes-2021. Diabetes Care. 2021, 44:S15-33. 10.2337\/dc21-S002","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41746","article-title":"A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus","volume":"15","author":"Jyotsna F","year":"2023","unstructured":"Jyotsna F, Mahfooz K, Patel T, et al.. A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus. Cureus. 2023, 15:e41746. 10.7759\/cureus.41746","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2239830","article-title":"Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"55","author":"Patel T","year":"2023","unstructured":"Patel T, Nageeta F, Sohail R, et al.. Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Ann Med. 2023, 55:2239830. 10.1080\/07853890.2023.2239830","journal-title":"Ann Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials","volume":"400","author":"Vaduganathan M","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, et al.. SGLT2-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials. Lancet. 2022, 400:757-7. 10.1016\/S0140-6736(22)01429-5","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.005","article-title":"Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms","volume":"34","author":"Petrie JR","year":"2018","unstructured":"Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018, 34:575-84. 10.1016\/j.cjca.2017.12.005","journal-title":"Can J Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12638","article-title":"Diabetes and hypertension: a comparative review of current guidelines","volume":"18","author":"Cryer MJ","year":"2016","unstructured":"Cryer MJ, Horani T, DiPette DJ. Diabetes and hypertension: a comparative review of current guidelines. J Clin Hypertens (Greenwich). 2016, 18:95-100. 10.1111\/jch.12638","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.09.005","article-title":"Patient-driven diabetes care of the future in the technology era","volume":"29","author":"Ashrafzadeh S","year":"2019","unstructured":"Ashrafzadeh S, Hamdy O. Patient-driven diabetes care of the future in the technology era. Cell Metab. 2019, 29:564-75. 10.1016\/j.cmet.2018.09.005","journal-title":"Cell Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/bios12090687","article-title":"Analytical challenges in diabetes management: towards glycated albumin point-of-care detection","volume":"12","author":"Rescalli A","year":"2022","unstructured":"Rescalli A, Varoni EM, Cellesi F, Cerveri P. Analytical challenges in diabetes management: towards glycated albumin point-of-care detection. Biosensors (Basel). 2022, 12:687. 10.3390\/bios12090687","journal-title":"Biosensors (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000946","article-title":"Recent advances in the management of proliferative diabetic retinopathy","volume":"34","author":"Pandit S","year":"2023","unstructured":"Pandit S, Ho AC, Yonekawa Y. Recent advances in the management of proliferative diabetic retinopathy. Curr Opin Ophthalmol. 2023, 34:232-6. 10.1097\/ICU.0000000000000946","journal-title":"Curr Opin Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1133-9","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"21","author":"Htay T","year":"2019","unstructured":"Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019, 21:45. 10.1007\/s11886-019-1133-9","journal-title":"Curr Cardiol Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200826135401","article-title":"Therapeutic advancements in the management of diabetes mellitus with special reference to nanotechnology","volume":"26","author":"Chauhan PS","year":"2020","unstructured":"Chauhan PS, Yadav D, Tayal S, Jin JO. Therapeutic advancements in the management of diabetes mellitus with special reference to nanotechnology. Curr Pharm Des. 2020, 26:4909-16. 10.2174\/1381612826666200826135401","journal-title":"Curr Pharm Des"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.2174\/1573399815666190115145702","article-title":"Type-3c diabetes mellitus, diabetes of exocrine pancreas - an update","volume":"15","author":"Bhattamisra SK","year":"2019","unstructured":"Bhattamisra SK, Siang TC, Rong CY, et al.. Type-3c diabetes mellitus, diabetes of exocrine pancreas - an update. Curr Diabetes Rev. 2019, 15:382-94. 10.2174\/1573399815666190115145702","journal-title":"Curr Diabetes Rev"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.03.028","article-title":"Recent advances in the management of diabetic retinopathy","volume":"24","author":"Dulull N","year":"2019","unstructured":"Dulull N, Kwa F, Osman N, Rai U, Shaikh B, Thrimawithana TR. Recent advances in the management of diabetic retinopathy. Drug Discov Today. 2019, 24:1499-509. 10.1016\/j.drudis.2019.03.028","journal-title":"Drug Discov Today"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2239","article-title":"Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy","volume":"28 Suppl 1","author":"Tesfaye S","year":"2012","unstructured":"Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012, 28 Suppl 1:8-14. 10.1002\/dmrr.2239","journal-title":"Diabetes Metab Res Rev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43882","article-title":"Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes","volume":"15","author":"Jyotsna F","year":"2023","unstructured":"Jyotsna F, Ahmed A, Kumar K, et al.. Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes. Cureus. 2023, 15:e43882. 10.7759\/cureus.43882","journal-title":"Cureus"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43697","article-title":"Advances in the management of diabetes mellitus: a focus on personalized medicine","volume":"15","author":"Sugandh F","year":"2023","unstructured":"Sugandh F, Chandio M, Raveena F, et al.. Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus. 2023, 15:e43697. 10.7759\/cureus.43697","journal-title":"Cureus"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102588","article-title":"Effects of testosterone therapy in adult males with hypogonadism and T2DM: a meta-analysis and systematic review","volume":"16","author":"Kumar S","year":"2022","unstructured":"Kumar S, Khatri M, Memon RA, et al.. Effects of testosterone therapy in adult males with hypogonadism and T2DM: a meta-analysis and systematic review. Diabetes Metab Syndr. 2022, 16:102588. 10.1016\/j.dsx.2022.102588","journal-title":"Diabetes Metab Syndr"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract13020041","article-title":"Treatment with testosterone therapy in type 2 diabetic hypogonadal adult males: a systematic review and meta-analysis","volume":"13","author":"Kumari K","year":"2023","unstructured":"Kumari K, Kumar R, Memon A, et al.. Treatment with testosterone therapy in type 2 diabetic hypogonadal adult males: a systematic review and meta-analysis. Clin Pract. 2023, 13:454-69. 10.3390\/clinpract13020041","journal-title":"Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/219219-novel-therapies-in-diabetes-a-comprehensive-narrative-review-of-glp-1-receptor-agonists-sglt2-inhibitors-and-beyond","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:42Z","timestamp":1707509502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/219219-novel-therapies-in-diabetes-a-comprehensive-narrative-review-of-glp-1-receptor-agonists-sglt2-inhibitors-and-beyond"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.51151","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}